TKG Advisors’s Eli Lilly LLY Stock Holding History

Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake
Trade Value Portfolio Weight Portfolio Position
2023
Q1
Sell
-3,426
Closed -$1.25M 101
2022
Q4
$1.25M Buy
3,426
+173
+5% +$61.3K 0.83% 36
2022
Q3
$1.05M Sell
3,253
-4,106
-56% -$1.3M 0.83% 33
2022
Q2
$2.39M Buy
7,359
+413
+6% +$124K 2.05% 17
2022
Q1
$1.99M Buy
6,946
+621
+10% +$160K 1.59% 22
2021
Q4
$1.75M Buy
+6,325
New +$1.6M 1.38% 24

Other funds holding LLY

TKG Advisors's LLY Position: Q1 2023 in Review

TKG Advisors sold out of Eli Lilly (LLY) in Q1 2023, closing a stake of 3,426 shares — an estimated $1.25M sold.

TKG Advisors first reported a position in LLY in Q4 2021 and held it in 5 quarters. The position peaked at $2.39M in Q2 2022. 2,614 funds tracked by Wall St. Rank hold LLY as of Q1 2023.

  • TKG Advisors reported no remaining Eli Lilly position as of Q1 2023 after selling out during the quarter.
  • TKG Advisors sold 3,426 Eli Lilly shares in Q1 2023, an estimated $1.25M.
  • TKG Advisors first reported a position in Eli Lilly in Q4 2021 and held it in 5 quarters.
  • TKG Advisors's Eli Lilly position peaked at $2.39M in Q2 2022.
  • 2,614 funds tracked by Wall St. Rank held Eli Lilly as of Q1 2023.

Based on TKG Advisors's 13F filing for Q1 2023, filed 19 Apr 2023.